论文部分内容阅读
目的观察恩替卡韦联合安络化纤丸的临床效应。方法选择74例慢性乙型肝炎肝硬化患者,随机分组:37例为治疗组,37例为对照组,治疗组口服恩替卡韦加安络化纤丸,恩替卡韦0.5mg 1次/日,安络化纤丸6g 3次/日,对照组口服恩替卡韦0.5mg 1次/日,两组用药总时间12个月,在3个月、6个月、12个月,24个月,分别按Child-Pugh分级并分别观察两组治疗前后肝功能、肝纤维化指标,HbeAg及HBV-DNA转阴率变化。结果两组患者肝功能无明显差异,Child-Pugh分级、肝纤维化指标联合组优于对照组,治疗组患者HA、IV-C、LN及PCIII明显降低,与对照组相比较(P<0.05),差异有统计学意义。治疗组患者HBV-DNA转阴例数为32例,转阴率为86.5%,对照组转阴例数为29例,转阴率为78.4%,差异无统计学意义;治疗组HBe Ag转阴例数为30例,转阴率为81.1%,对照组转阴例数为28例,转阴率为75.6%,差异无统计学意义。结论恩替卡韦联合安络化纤丸治疗慢性乙型肝炎肝硬化有显著抑制病复制,肝功能、肝纤维化指标得到明显改善,疗效确切,值得临床推广。
Objective To observe the clinical effect of entecavir and Xinluo Chemical Fiber Pills. Methods Seventy-four patients with chronic hepatitis B cirrhosis were randomly divided into treatment group (n = 37) and control group (n = 37). Entecavir 0.5 mg once daily, 3 times a day. The control group was given 0.5 mg of entecavir once a day for a total of 12 months. The three groups were divided into three groups: Child-Pugh group (3 months, 6 months, 12 months and 24 months) The changes of liver function, hepatic fibrosis index, HbeAg and HBV-DNA negative rate before and after treatment were observed. Results There was no significant difference in liver function between the two groups. The Child-Pugh grading and liver fibrosis index were better than the control group. The HA, IV-C, LN and PCIII in the treatment group were significantly lower than those in the control group (P <0.05 ),The difference was statistically significant. In the treatment group, the number of HBV-DNA negative cases was 32 cases, the negative conversion rate was 86.5%, the negative cases in the control group was 29 cases, the negative conversion rate was 78.4%, the difference was not statistically significant; HBeAg negative The number of cases was 30 cases, the negative conversion rate was 81.1%, the control group, the number of negative cases was 28 cases, the negative conversion rate was 75.6%, the difference was not statistically significant. Conclusion Entecavir combined with Anluo Huaxian Wan treatment of chronic hepatitis B cirrhosis significantly inhibited disease replication, liver function, liver fibrosis index was significantly improved, the exact effect, worthy of clinical promotion.